Skip to main content
SpringerLink
Log in

Cardiac structure and function after treatment with adrenergic blocking agents

  • Chapter
The Heart in Hypertension

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 98))

  • 107 Accesses

Abstract

Cardiac hypertrophy and left ventricular dysfunction constitute the main forms of cardiac involvement secondary to elevation of arterial pressure. Impairment of coronary vasodilator reserve and cardiac arrhythmias are also related to hypertension though less well recognized problems. Such changes in cardiac anatomy and funcion in hypertensive patients are not only due to increase in pressure overload but also to other modulating mechanisms. The sympathetic nervous system plays a central role among these mechanisms. Adrenergic blocking agents by both relieving the pressure overload and interfering with sympathetic functions can thus produce important changes in cardiac structure and function. Regression of cardiac hypertrophy, alterations in ventricular systolic and diastolic functions and improvement of coronary vasodilator reserve were all reported following adrenergic blockade therapy [1, 13]. Regression of ischemic changes and left ventricular strain pattern in the electrocardiogram can be demonstrated after the use of many of these drugs [14].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Poblete PF, Kyle MC, Pipberger HV, Freis ED (1973): Effect of treatment on morbidity in hypertension. Veterans Administration Cooperative Study on Antihypertensive Agents: Effect on the electrocardiogram. Circulation 48: 481–490.

    PubMed  CAS  Google Scholar 

  2. Ibrahim MM, Tarazi RC, Dustan HP, Gifford RW (1977): Electrocardiogram in evaluation of resistance to antihypertensive therapy. Archives on Internal Medicine 137: 1125–1129.

    Article  CAS  Google Scholar 

  3. Ibrahim MM, Madkour MA, Mossallam R (1981): Factors influencing cardiac hypertrophy in hypertensive patients. Clinical Science 61: 1055–1085.

    Google Scholar 

  4. Sonotani N, Kubo S, Nishioka A, Takatsu T (1981): Electrocardiographic and echocardiographic changes after one to two-years treatment of hypertension: Analysis of voltages (SV1 + RV5), wall thickness, cavity, mass, and hemodynamics of the left ventricle. Japanese Heart J 22: 325–333.

    Article  CAS  Google Scholar 

  5. Corea L, Bentivoglio M, Verdecchia P (1981): Reversal of left ventricular hypertrophy in essential hypertension by early and long-term treaatment with methyldopa. Clinical Trials J 18: 380–394.

    Google Scholar 

  6. Drayer JIM, Gardin JM, Weber MA, Aronow WS (1982): Changes in cardiac anatomy and function during therapy with alpha-methyldopa: An echocardiographic study. Current Therapeutic Research 32: 856–865.

    Google Scholar 

  7. Rowlands DB, Ireland MA, Glover DR, McLeay RAB, Stolland TJ, Littler WA (1981): The relationship between ambulatory blood pressure and echocardiographically assessed left ventricular hypertrophy. Clinical Science 61: 1015–1035.

    Google Scholar 

  8. Ibrahim MM Madkour MA, Mossallam R (1980): Effect of atenolol on left ventricular function in hypertensive patients. Circulation 62: 1036–1046.

    PubMed  CAS  Google Scholar 

  9. Ibrahim MM, Madkour MA (1983): Effect of cardiac hypertrophy on left ventricular performance in hypertensive patients. J Hypertension 1: 275s–277s.

    Google Scholar 

  10. Ibrahim MM, Emile H, Madkour MA, Said GE (1985): Contractile performance following regression of left ventricular hypertrophy in hypertensive patients. J Hypertension 3: 461s–463s.

    Google Scholar 

  11. Fouad FM, Slominski MJ, Tarazi RC, Gallagher JH (1983): Alterations in left ventricular filling with beta-adrenergic blockade. Am J Cardiol 51: 161–164.

    Article  PubMed  CAS  Google Scholar 

  12. Ibrahim MM, Zaghloul SS, Helmi SM (1987): Effect of regression of left ventricular hypertrophy on diastolic function in hypertensive patients. J Hypertension 5: 411s.

    Google Scholar 

  13. Strauer BE (1980): Hypertensive Heart Disease, pp 84–85. Berlin-Heidelberg-New York: Springer Verlag.

    Google Scholar 

  14. Frohlich ED (1983): The heart in hypertension, in Generst J, Kuchel O, Hamet P, Cantin M (eds), Hypertension, Physiopathology and Treatment, 2nd edn, pp 791–810. New York: McGraw-Hill.

    Google Scholar 

  15. Folkow B (1982): Physiological aspects of primary hypertension. Physiologic Rev 62: 347–504.

    CAS  Google Scholar 

  16. Kallfelt BJ, Hjalmareson AC, Isaksson OG (1976): In vitro effects of catecholamines on protein synthesis in perfused rat heart. J Molec & Cellular Cardiol 8: 787–802.

    Article  CAS  Google Scholar 

  17. Sen S, Tarazi RC, Kharallah PA, Bumpus FM (1974): Cardiac hypertrophy in spontaneously hypertensive rats. Circulation Research 35: 775–781.

    PubMed  CAS  Google Scholar 

  18. Schwartz A (1971): Studies on mitochondria from normal, hypertrophied and falling myocardium, in: Albert NR (ed), Cardiac Hypertrophy, pp 522–536. New York: Academic Press.

    Google Scholar 

  19. Wollam GL, Hall WD, Porter VD, Douglas MB, Unger DJ, Blumenstein BA, Cotsonis GA, Knudtson ML, Feiner JM, Schlant RC (1983): Time course of regression of left ventricular hypertrophy in treated hypertensive patients. American Journal of Medicine, Proceedings of a Symposium: Left Ventricular Hypertrophy in Essential Hypertension, pp 100–110.

    Google Scholar 

  20. Tamanek RJ, Davis JW, Anderson SC (1979): The effects of alpha methyldopa on cardiac hypertrophy in spontaneously hypertensive rats: Ultrastructural, sterological, and morphometric analysis. Cardiovascular Research 13: 173–182.

    Article  Google Scholar 

  21. Rowlands DB, Glover DR, Ireland MA (1982): Assessment of left ventricular mass and its response to antihypertensive treatment. Lancet 1982/2: 467–470.

    Article  Google Scholar 

  22. Fouad FM, Nakashima Y, Tarazi RC, Salcedo EE (1982): Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa. Lack of association with blood pressure control. Am J Cardiol 49: 795–801.

    Article  PubMed  CAS  Google Scholar 

  23. Strauer BE, Bayer F, Brecht HM, Motz W (1985): The influence of sympathetic nervous activity on regression of cardiac hypertrophy. J Hypertension 3: 39s–44s.

    Article  Google Scholar 

  24. Sen S, Tarazi RC, Bumpus FM (1977): Cardiac hypertrophy and antihypertensive therapy. Cardiovascular Research, 11: 427–433.

    Article  PubMed  CAS  Google Scholar 

  25. Sen S (1987): Factors regulating myocardial hypertrophy in hypertension. Circulation 75(suppl I): I 81–I 84.

    CAS  Google Scholar 

  26. Pauletto P, Dalla Libera L, Vescovo G (1985): Propranolol induced changes in ventricular isomyosin composition in the rat. Am Heart J 109: 1269–1273.

    Article  PubMed  CAS  Google Scholar 

  27. Laura IK, Sen S (1984): Myosin isozyme distribution pattern and cardiac performance following antihypertensive therapy in spontaneously hypertensive rats (abstract). Federation Proceedings 43: 650.

    Google Scholar 

  28. Weber KT, Janicki JS, Pick R, Abrahams C, Shroff SG, Bashey RI, Chen RM (1987): Collagen in the hypertrophied, pressure-overloaded myocardium. Circulation 75(suppl I): I 40–I 47.

    CAS  Google Scholar 

  29. Cutiletta AF, Dowell RT, Rudrick M, Archilla RA, Zak R (1979): Regression of myocardial hypertrophy (1). J Molec & Cellular Cardiol 7: 761–780.

    Google Scholar 

  30. Sen S (1983): Regression of cardiac hypertrophy. Experimental animal model. American Journal of Medicine, Proceedings of a Symposium: Left Ventricular Hypertrophy in Essential Hypertension, pp 87–93.

    Google Scholar 

  31. Tarazi RC (1978): Hemodynamic effect of aldomet, in Maxwell MH (ed), Aldomet in the Management of Hypertension, pp 73–75. West Point, Pa: Merck Sharp and Dohme.

    Google Scholar 

  32. Ulrych M, Frohlich ED, Dustan HP, Page IH (1968): Immediate hemodynamic effects of beta adrenergic blockade with propranolol in normotensive and hypertensive man. Circulation 37: 411–416.

    PubMed  CAS  Google Scholar 

  33. Tarazi RC, Dustan HP (1972): Beta-adrenergic blockade in hypertension, practical and theoretical implications of long-term hemodynamic variations. Am J Cardiol 29: 633–640.

    Article  PubMed  CAS  Google Scholar 

  34. Hansson L (1986): Hemodynamics of metoprolol and pindolol in systemic hypertension with particular reference to reversal of structural vascular changes. Am J Cardiol 57: 29c–32c.

    Article  PubMed  CAS  Google Scholar 

  35. Reybrouck T, Amery A, Billiet L (1977): Hemodynamic response to graded exercise after chronic beta-adrenergic blockade. J Applied Physiol 42: 133–138.

    CAS  Google Scholar 

  36. Krauss XH, Schalekamp MADH, Kolsters G, Zaad GA, Birkenhager WH (1972): Effects of chronic beta-adrenergic blockade on systemic and renal hemodynamic responses to hyperosmotic saline in hypertensive patients. Clinical Science 43: 385–391.

    PubMed  CAS  Google Scholar 

  37. Julius S, Pascual AV, Abbrecht PT, London R (1972): Effect of beta-adrenergic blockade on plasma volume in human subjects. Proceedings of the Society for Experimental Biology and Medicine 140: 982–985.

    PubMed  CAS  Google Scholar 

  38. DeMaria AN, Newmann A, Schubart PJ, Lee G, Mason DT (1979): Systemic correlation of cardiac chamber size and ventricular performance determined with echocardioggraphy and alterations in heart rate in normal persons. Am J Cardiol 43: 1–10.

    Article  PubMed  CAS  Google Scholar 

  39. Atterhog JH, Duner H, Pernow B (1976): Experience with pindolol, a beta receptor blocker, in treatment of hypertension. Am J Medicine 60: 872–880.

    Article  CAS  Google Scholar 

  40. Hary JD, Knapp MF, Linden RJ (1974): The actions of a new beta-adrenergic blocking drug, ICI 66082, on the rabbit papillary muscle and on the dog heart. Br J Pharmacol 51: 169–174.

    Google Scholar 

  41. Lichtlen P, Amende I, Simon R, Engel JH, Hundeshagen H (1977): Left ventricular function and regional myocardial blood flow after atenolol in normals and patients with coronary artery disease. Postgraduate Medical J 53(Suppl 3): 85–93.

    CAS  Google Scholar 

  42. Ibrahim MM, Mossallam R (1981): Clinical evaluation of atenolol in hypertensive patients. Circulation 64: 368–374.

    Article  PubMed  CAS  Google Scholar 

  43. Nayler WG, McInnes I, Carson V, Swann J, Low TE (1969): The combined effect of atropine and B-adrenergic receptor antagonists on left ventricular function and coronary blood flow. Am Heart J 77: 246–258.

    Article  PubMed  CAS  Google Scholar 

  44. Sundberg S, Gordin A (1986): Influence of beta blockade and intrinsic sympathomimetic activity on hemodynamics, inotropy and respiration at rest and during exercise. Am J Cardiol 57: 1394–1399.

    Article  PubMed  CAS  Google Scholar 

  45. Nayle WG (1970): The effect of beta-adrenergic blocking drugs on myocardial function; an explanation at the subcellular level. Postgraduate Medicali 46 (suppl): 90–96.

    Google Scholar 

  46. Scales B, Mcintosh DAD (1968): Effect of propranolol and its optical isomers on the radio calcium uptake and the adenosine triphosphatase of skeletal and cardiac sarcoplasmic reticulum fractions (SRF). J Pharmacol Exper Therapeutics 160: 261–270.

    CAS  Google Scholar 

  47. Lompre A, Schwartz K, d’Aglis A, La Combe G, Thiem NU, Swyngedauis B (1979): Myosin isoenzyme redistribution in chronic heart overload. Nature 282: 105–112.

    Article  PubMed  CAS  Google Scholar 

  48. Mercadier JJ, Lompre C, Wisnewsky JL, Samuel J, Bervovici B, Swyngedauis B (1981): Circulation Research 49: 525–532.

    PubMed  CAS  Google Scholar 

  49. Van Zwieten PA, Theolen MJC, Timmermans PMW (1984): The hypotensive activity and side effects of methyldopa, Clonidine, and guanfacine. Hypertension 6(suppl II): II 28–II 33.

    Google Scholar 

  50. Onesti G, Brest AN, Novack P, Kasparian H, Moyer JH (1964): Pharmacodynamic effects of alpha-methyldopa in hypertensive subjects. Am Heart J 67: 32–38.

    Article  PubMed  CAS  Google Scholar 

  51. Constantine JW, McShane WK (1968): Analysis of cardiovascular effects of 2-(2,6-dichlorophenylamine)-2-imidazoline hydrochloride (Catapres). Europ J Pharmacol 4: 109–123.

    Article  CAS  Google Scholar 

  52. Lund-Johansen P (1972): Hemmodynamic changes in long term α-methyldopa therapy of essential hypertension. Acta Med Scand 192: 221–226.

    Article  PubMed  CAS  Google Scholar 

  53. Hoefke W (1980): Clonidine, in Scriabine A (ed), Pharmacology of Antihypertensive Drugs, pp 55–61. New York: Raven Press.

    Google Scholar 

  54. Shah RS, Walker BR, Vanov SK, Heifant RH (1976): Guanabenz effects on blood pressure and noninvasive parameters of cardiac performance in patients with hypertension. Clin Pharmacol & Therap 19: 732–737.

    CAS  Google Scholar 

  55. Walker BR, Shah RS, Ramanathan KB, Vanov SK, Heifant RH (1977): Guanabenz and methyldopa on hypertension and cardiac performance. Clin Pharmacol & Therap 22: 868–874.

    CAS  Google Scholar 

  56. Lund-Johansen P (1975): Hemodynamic changes at rest and during exercise in long-term prazosin therapy for essential hypertension. Postgraduate Medicine 58 (suppl): 45–52.

    Google Scholar 

  57. Stokes GS, Oates HF (1978): Prazosin: New alpha-adrenergic blocking agent in treatment of hypertension. Cardiovasc Med 3: 41–57.

    CAS  Google Scholar 

  58. Scriabine A (1980): Prazosin, in Scriabine A (ed), Pharmacology of Antihypertensive Drugs, pp 153. New York: Raven Press.

    Google Scholar 

  59. Riggs K, Mason DT, Lee G (1978): Direct inotropic effects of the afterload reducing agents, hydralazine and prazosin, evaluated in isolated cat papillary muscle preparation. Am J Cardiol 41: 366.

    Article  Google Scholar 

  60. Koshy MC, Mickley D, Bourgoignie J, Blaufox MD (1977): Physiologic evaluation of a new antihypertensive agent: Prazosin HCl. Circulation 55: 533–537.

    PubMed  CAS  Google Scholar 

  61. Mehta J, Iacona M, Feldman RL, Pepine CJ, Conti CR (1978): Comparative hemodynamic effects of intravenous nitroprusside and oral prazosin in refractory heart failure. Am J Cardiol 41: 925–930.

    Article  PubMed  CAS  Google Scholar 

  62. Kisin I, Yazhakov S (1976): Effects of reserpine, guanethidine and methyldopa on cardiac output and its distribution. Europ J Pharmacol 35: 253–260.

    Article  CAS  Google Scholar 

  63. Lee WC, Shideman FE (1959): Role of myocardial catecholamines in cardiac contractility. Science 129: 967–968.

    Article  PubMed  CAS  Google Scholar 

  64. Wileken DEL, Brender RD, Shorey CD, McDonald GJ (1967): Reserpine: Effect on structure of heart muscle. Science 157: 1332–1334.

    Article  Google Scholar 

  65. Braunwald E, Chidsey CA, Harrison DC, Gaffney TE, Kahler RI (1963): Studies on the function of the adrenergic nerve endings in the heart. Circulation 28: 958–969.

    PubMed  CAS  Google Scholar 

  66. Chamberlain DA, Howard J (1964): Guanethidine and methyldopa: A hemodynamic study. Br Heart J 26: 528–536.

    Article  PubMed  CAS  Google Scholar 

  67. Gaasch WH, Levine HJ, Quinones MA, Alexander JK (1976): Left ventricular compliance: mechanisms and clinical implications. Am J Cardiol 38: 645–653.

    Article  PubMed  CAS  Google Scholar 

  68. Grossman W, McLaurin L (1976): Diastolic properties of the left ventricle. Ann Internal Med 84: 316–326.

    CAS  Google Scholar 

  69. Brutsaert DL, Housmans PR, Goethals MA (1980): Dual control of relaxation: Its role in the ventricular function in the mammalian heart. Circulation Research 47: 637–652.

    PubMed  CAS  Google Scholar 

  70. Fioretti R, Brower R, Geert T, Meester T, Serruys P (1980): Interaction of left ventricular filling and filling during early diastole in human subjects. Am J Cardiol 46: 197–203.

    Article  PubMed  CAS  Google Scholar 

  71. Innouye IK, Massie BM, Loge D, Simpson P, Tubau JF (1984): Failure of antihypertensive therapy with diuretic, betablocking and calcium channel-blocking drugs to consistently reverse left ventricular diastolic filling abnormalities. Am J Cardiol 53: 1583–1587.

    Article  Google Scholar 

  72. Shigakawa M, Dougherty JP, Katz AM (1978): Reaction mechanism of calcium dependent ATP hydrolysis by skeletal muscle sarcoplasmic reticulum in the absence of added alkali salts. J Biological Chemistry 253: 1442–1450.

    Google Scholar 

Download references

Authors
  1. M. Mohsen Ibrahim
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine and Hypertension Research Center, Broussais Hospital, Paris, France

    M. E. Safar

  2. Cleveland Clinic Foundation, Cleveland, Ohio, USA

    F. Fouad-Tarazi

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Kluwer Academic Publishers

About this chapter

Cite this chapter

Ibrahim, M.M. (1989). Cardiac structure and function after treatment with adrenergic blocking agents. In: Safar, M.E., Fouad-Tarazi, F. (eds) The Heart in Hypertension. Developments in Cardiovascular Medicine, vol 98. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0941-0_28

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-0941-0_28

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6913-7

  • Online ISBN: 978-94-009-0941-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation